Gilead Sciences has agreed a deal with machine - learning start - up Insitro to help the drug maker develop treatments for liver disease . Gilead will pay an initial $ 15 million to the San Francisco - based start - up , with a potential $ 1bn in payments at later dates if certain targets are met . Through the deal , Insitro will develop and apply machine learning to the task of designing proteins that could be used for innovative drugs to treat non - alcoholic steatohepatitis , or NASH .
Gilead Sciences has agreed a deal with machine-learning start-up Insitro to help the drug maker develop treatments for liver disease. Gilead will pay an initial $15m to the San Francisco-based start-up, with a potential $1bn in payments at later dates if certain targets are met. Through the deal, Insitro will develop and apply machine algorithms to the task of identifying proteins that could be targets for innovative drugs to treat non-alcoholic steatohepatitis, or NASH.